All GLG News Analyses Filed Under: Infectious Disease
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
Will the new rapid test for C difficile be an important advance?
July 19, 2009
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com
In patients with C difficile colitis, the usual situation is that when the diarrhea stops during or after treatment, isolation can stop. The biggest benefit of this new test is in validating preliminary identification of newly infected or relapsing patients so that isolation will be used appropriately.
-
Peter BornsteinPartner and Consultant in Infectious DiseasesSt. Paul Infectious Disease Associates, Ltd
Potential game changer for patients and hospitals regarding C. difficile colitis
July 18, 2009
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com
Clostridium difficile-associated colitis is a disabling, and potentially life-threatening infection. Moreover, hospitals spend great resources in isolating patients with this disease to prevent infection within the hospital. This new technology from Cepheid offers faster, and more accurate diagnosis, leading to potentially quicker treatment for patients, but potentially huge savings for hospitals, that can shorten isolation periods for these patients.
-
June 2, 2009
Malaria vaccine could be available by 2011: report | www.hindu.com
The new Anti-Malarial vaccine could offer hope to millions of third world patients who die each year from mosquito born Malaria.
-
Evaluation of Influenza Vaccines
May 20, 2009
Novartis receives swine flu virus | newsinfo.inquirer.net
Scientists, medical professionals and the public know that by the time new flu vaccines are produced for use that the specific outbreak is far into the past and the vaccine is no longer in need and is destroyed. Novartis and other vaccine production companies need to dedicate more effort in evaluation of existing and new vaccines.
-
Implications for Influenza Antivirals and Vaccines
May 1, 2009
As Nations Try to Contain Flu, N.Y. Cases Are Confirmed | www.nytimes.com
The current situation is rapidly evolving and new and changing information will influence guidance. Much has yet to be learned about this new virus. Yet, we currently have a window of opportunity to ramp up preparedness and response activities.
-
Frank MalinoskiPresidentTD Consultancy, LLC
Balancing the Problem and the Panic Around Swine Flu
May 1, 2009
As Nations Try to Contain Flu, N.Y. Cases Are Confirmed | www.nytimes.com
Panic in the US is not warranted Attention to what is happening in the rest of the world is warranted WHO would be driven to raise the alert level further if this swine flu virus enters and spreads in countries like India, China, and the poorer countries of Latin America and Africa WHO would raise the alert level if this swine flu recombines with a Southern Hemisphere seasonal flu, generating a more lethal and/or antiviral resistant strain Vaccine seeds need to be developed now. Vaccination policies need to ensure people will be lined up for vaccine in the fall for the Northern Hemisphere and we need vaccines for both seasonal and this swine vaccine. Policy leaders need to decide if they will delay seasonal vaccine in favor of a swine vaccine and with manufacturers decide how to produce enough vaccine to curtail the possible pandemic.
-
April 30, 2009
As Nations Try to Contain Flu, N.Y. Cases Are Confirmed | www.nytimes.com
Yes, this new strain of influenza will certainly spread, and there is still no data about protection afforded by prior vaccination. The high morbidity and mortality in Mexico vs. that seen so far in the US is puzzling, and will await further clarification.
-
April 29, 2009
New TB vaccine candidate enters phase IIb proof-of-concept trial in South Africa | www.pharmabiz.com
TB poses a great threat in South Africa and in the world generally. South Africa has declared TB in South Africa as having reached a state of emergency and therefore is a crisis.It is therefore very crucial to ackowledge and support such initiatives especially that seeks to provide prevention efforts towards the spread of TB.I do not have documentation or background information to this clinical trial but I have couple of questions mainly for the Principal Investigator or even a Study Director. My questions are as follows:1. What are the reasons behind choosing Cape Town as a study site because KZN mainly the Ethekwini District has the highest number of PTB cases as well those of MDR cases.2. With regards to the age range of the study participants are they also considering HIV factor, those kids who might be infected with HIV, what implications will then their participation pose on their health in terms of drug resistance 3. Are they also considering other strains of TB other than PTB
-
April 28, 2009
As Nations Try to Contain Flu, N.Y. Cases Are Confirmed | www.nytimes.com
The current soon-to-be pandemic of "swine" flu is sweeping the globe. This past year's vaccine does not include this strain, nor did last year's. Vaccine manufacturers will have less credibility for selling next year's product; on the brighter side, antiviral manufacturers will sell out their backlogged products. Hospitals and doctors' offices will be overwhelmed, first by the "worried well" and then by the actually sick.
-
Frank MalinoskiPresidentTD Consultancy, LLC
How do we respond to the new influenza threat?
April 27, 2009
As Nations Try to Contain Flu, N.Y. Cases Are Confirmed | www.nytimes.com
Swine flu has struck and people are concerned. Antivirals are available and look like they will work (for now). The CDC reports that there is no vaccine, but is there hope that last year's vaccines will help prevent infection? Is the government going to launch a campaign to make a swine flu vaccine available? Who will step up and how long will it take?
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Infectious Disease News
-
Flu Emergency Calls for all Alternatives to be Considered
October 27, 2009
-
Starpharma gets US patent for use of VivaGel for protection against STIs
September 29, 2009
-
September 25, 2009
-
A September to Watch-- and Remember: H1N1 Vaccine 1st Tipping Point Positive
September 11, 2009
-
Can we trust Sinovac swine flu results?
September 9, 2009